J&J to buy US biotech Taris and its bladder cancer drug devi...

Johnson & Johnson is to buy the privately-owned biotech Taris, and a device that can deliver cancer drugs to the bladder.

BeiGene's Brukinsa fails to beat AbbVie/J&J's Ibrutinib in W...

BeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white blood cell cancer Waldenstrom’s macroglublinemia (WM).

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

FDA nod for AZ’s Calquence sets up new Imbruvica showdown

13th Annual Pharma Resource Planning and Portfolio Managemen...

Prioritizing Projects with Tools, Data, and Governance

Janssen taps wearable tech in Invokana heart failure trial